Full Text View
Tabular View
No Study Results Posted
Related Studies
Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair (StAR)
This study is currently recruiting participants.
Verified January 2012 by LifeCell
Study NCT01083472   Information provided by LifeCell

First Received on March 8, 2010.   Last Updated on January 10, 2012   History of Changes

March 8, 2010
January 10, 2012
March 2010
April 2013   (final data collection date for primary outcome measure)
Hernia occurrence [ Time Frame: Month 12 after repair ] [ Designated as safety issue: Yes ]
Hernia occurrence will be assessed by clinical evaluation. At Month 12 and at any time during the study if hernia occurrence is clinically suspected, a magnetic resonance image (MRI) will be obtained.
Same as current
Complete list of historical versions of study NCT01083472 on ClinicalTrials.gov Archive Site
  • Re-operation for abdominal wall repair [ Time Frame: within 12 months of repair ] [ Designated as safety issue: Yes ]
    need for reoperation to re-repair the original defect
  • Incidence of acute complications requiring intervention (medical or surgical) [ Time Frame: First 30 days post-repair ] [ Designated as safety issue: Yes ]
    Incidence of complications requiring intervention (medical or surgical), including occurrence of fascial dehiscence, wound infection and seroma
recurrence of fascial dehiscence [ Time Frame: First 30 days post-repair of initial dehiscence ] [ Designated as safety issue: Yes ]
recurrence of fascial dehiscence will be clinically evaluated
 
Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair (StAR)
A Multicenter, Prospective, Single-Blind, Randomized, Controlled Study of the Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair

The objective of this study is to compare the incidence of post-repair wound related complications, including hernia occurrence/recurrence, between challenging abdominal wall defects repaired with Strattice(TM) Reconstructive Tissue Matrix (TM) and those managed by standard repair. It is hypothesized that the use of Strattice(TM) TM to reinforce the repair will reduce the incidence of these post-repair complications.

This is a prospective, multicenter, single-blind, randomized, longitudinal, cross-over evaluation of the repair of challenging abdominal wall defects using Strattice(TM) TM or standard surgical repair. These abdominal wall defects can be acute or chronic, and include midline, transverse (including flank) as well as Pfannenstiel incisions. The skin may be closed (fascial dehiscence or incisional hernia) or open (patient with open abdomen or acute fascial dehiscence) with or without evisceration. Patients randomized to the control group who require a re-operation to perform the planned final repair or due to failure of the initial repair within 12 months, will be offered repair with Strattice™ TM (i.e. "crossed over") or if such repair not performed, the patient will have completed the study. An adaptive study design will be used to validate the initial conditional power of the study and a balanced randomization, based upon the three conditions (type of defect [dehiscence, hernia repair or open abdomen], morbidity [POSSUM score] and time since exposure of abdominal fascia/viscera) will be used to equally distribute subjects between groups.

The primary endpoint of this study is hernia occurrence at 12 months post repair and secondary endpoints include re-operation for abdominal wall repair within 12 months, incidence of complications requiring intervention(medical or surgical) within the first 30 days after repair,, length of hospitalization and resource utilization, and all cause mortality.

Subjects will be enrolled and randomized to receive Strattice(TM) TM reinforcement of repair or standard of care repair (i.e. suture alone or suture with absorbable mesh) and followed at set timepoints to observe incision site repair for surgical site events, including reoperation and hernia occurrence.

Interventional
Phase IV
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Hernia
  • Surgical Wound Dehiscence
  • Device: Strattice(TM) Reconstructive Tissue Matrix
    Strattice(TM) TM will be used to support the repair of abdominal wall defect
  • Procedure: Suture/suture with absorbable mesh
    Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
  • Active Comparator: Strattice(TM) TM repair
    Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
    Intervention: Device: Strattice(TM) Reconstructive Tissue Matrix
  • Active Comparator: Standard of Care repair
    Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
    Intervention: Procedure: Suture/suture with absorbable mesh

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
April 2014
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • adults (18years of age or older) who is able to provide written informed consent for study participation
  • has need of surgical intervention for repair of (potentially) contaminated abdominal wall defect of >3cm and <22cm in length, where the viscera have not been exposed for more than 15 days in case of open abdomen(skin and fascia open).
  • Is willing and able to return for all scheduled & required study visit.

Exclusion Criteria: at the time of randomization

  • severe systemic sepsis
  • frank pus in the wound, a fistula that will not be closed at the time of surgery or intra-abdominal abscess in surgical area,
  • ongoing necrotizing pancreatitis,
  • Is on chronic immunosuppressive therapy, or other medication that influences wound healing
  • requires only short-term temporary closure,
  • requires a synthetic, non-absorbable mesh to close the abdominal wall defect
  • is unable to undergo general anesthesia,
  • has other major organ system dysfunction or disorder that would jeopardize subject completing the 24 month study.
  • Is unable to undergo an MRI scan
Both
18 Years and older
No
Contact: Sandra van Guldener +31-20-4260038 sguldene@kci1.com
Contact: Randi Rutan +1-908-947-1349 rrutan@lifecell.com
France,   Germany,   Italy,   Netherlands,   Spain,   United Kingdom
 
NCT01083472
LFC2009.01.01
Yes
( LifeCell )
LifeCell
 
Principal Investigator: Angus JM Watson Raigmore Hospital, Inverness Scotland, National Health Service, UK
Principal Investigator: Berndt Reith Klinikum Konstanz, Konstanz Germany
Study Chair: Johannes Jeekel
LifeCell
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP